Cargando…

Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic BRCA2-mutated Ovarian Cancer with Brain Metastases: A Case Report and Literature Review

Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1–2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tao, Mengyu, Cheng, Jiejun, Wu, Xia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7755878/ https://www.ncbi.nlm.nih.gov/pubmed/33376347 http://dx.doi.org/10.2147/OTT.S281302

Ejemplares similares

Niraparib and Advanced Ovarian Cancer: A Beacon in the Non-BRCA Mutated Setting
por: Maiorano, Mauro Francesco Pio, et al.
Publicado: (2023)

Cost-effectiveness of fuzuloparib compared to routine surveillance, niraparib and olaparib for maintenance treatment of patients with germline BRCA1/2 mutation and platinum-sensitive recurrent ovarian carcinoma in China
por: Nie, Jing, et al.
Publicado: (2023)

New perspective on maintenance therapies for platinum- sensitive recurrent ovarian cancer in women with germline and somatic mutations in BRCA1 and BRCA2 genes
por: Vergote, I, et al.
Publicado: (2016)

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer
por: Vitiello, Pietro Paolo, et al.
Publicado: (2021)

Germline ATM Mutations Detected by Somatic DNA Sequencing in Lethal Prostate Cancer
por: Grochot, Rafael, et al.
Publicado: (2023)

BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing
por: Mafficini, Andrea, et al.
Publicado: (2016)

Germline and Somatic BRCA1/2 Mutations in 172 Chinese Women With Epithelial Ovarian Cancer
por: You, Yan, et al.
Publicado: (2020)

Prevalence and clinical significance of BRCA1/2 germline and somatic mutations in Taiwanese patients with ovarian cancer
por: Chao, Angel, et al.
Publicado: (2016)

Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer
por: Eoh, Kyung Jin, et al.
Publicado: (2020)

Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer
por: Chen, Bo, et al.
Publicado: (2020)

Influence of BRCA1 Germline Mutations in the Somatic Mutational Burden of Triple-Negative Breast Cancer
por: Ferreira, Elisa Napolitano, et al.
Publicado: (2019)

Germline Testing for Patients With BRCA1/2 Mutations on Somatic Tumor Testing
por: Vlessis, Katherine, et al.
Publicado: (2019)

Germline ATM mutation and somatic PIK3CA and BCOR mutations found in an infant with aggressive orbital embryonal rhabdomyosarcoma
por: Jaru-ampornpan, Pimkwan, et al.
Publicado: (2021)

BRCA germline mutation test for all woman with ovarian cancer?
por: Paradiso, A. V., et al.
Publicado: (2019)

Prevalence of deleterious ATM germline mutations in gastric cancer patients
por: Huang, Dong-Sheng, et al.
Publicado: (2015)

Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil
por: Maistro, Simone, et al.
Publicado: (2016)

Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Niraparib for ovarian cancer
Publicado: (2021)

Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2
por: Ligtenberg, M J L, et al.
Publicado: (1999)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

BRCA1 and BRCA2 Germline Mutations Screening in Algerian Breast/Ovarian Cancer Families
por: Cherbal, Farid, et al.
Publicado: (2010)

Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: the EORTC 1307-BCG/BIG5–13/TESARO PR-30–50–10-C BRAVO Study
por: Turner, Nicholas C., et al.
Publicado: (2021)

Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma
por: Zhang, Jie Qing, et al.
Publicado: (2021)

Frequency of Germline and Somatic BRCA1 and BRCA2 Mutations in Prostate Cancer: An Updated Systematic Review and Meta-Analysis
por: Valsecchi, Anna Amela, et al.
Publicado: (2023)

BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families
por: Claes, K, et al.
Publicado: (2004)

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcome
por: Ashour, Mohamed, et al.
Publicado: (2019)

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers
por: Przybytkowski, Ewa, et al.
Publicado: (2020)

The germline mutational landscape of BRCA1 and BRCA2 in Brazil
por: Palmero, Edenir Inêz, et al.
Publicado: (2018)

Positive response to niraparib in chemo-refractory patients with metastatic appendiceal mucinous adenocarcinoma harboring ATM mutations: A case report
por: Wang, Junhui, et al.
Publicado: (2023)

First-line Rucaparib Plus Bevacizumab Maintenance Completed One-Year in Germline BRCA1-Mutated Advanced Ovarian Cancer
por: Roy, Somnath, et al.
Publicado: (2022)

Author Correction: Neoadjuvant study of niraparib in patients with HER2-negative, BRCA-mutated, resectable breast cancer
por: Spring, Laura M., et al.
Publicado: (2022)

Niraparib: A Review in First-Line Maintenance Therapy in Advanced Ovarian Cancer
por: Lee, Arnold
Publicado: (2021)

Evaluation of models to predict BRCA germline mutations
por: Kang, H H, et al.
Publicado: (2006)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

Somatic and Germline BRCA 1 and 2 Mutations in Advanced NSCLC From the SAFIR02-Lung Trial
por: Remon, Jordi, et al.
Publicado: (2020)

BRCA1 and BRCA2 germline mutation analysis in the Indonesian population
por: Purnomosari, Dewajani, et al.
Publicado: (2007)

Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in high-grade serous ovarian cancers in the maintenance setting
por: Dougherty, Brian A., et al.
Publicado: (2017)

Patterns and duration of primary and recurrent treatment in ovarian cancer patients with germline BRCA mutations
por: Jorge, Soledad, et al.
Publicado: (2019)

Psychosexual Morbidity in Women With Ovarian Cancer: Evaluation by Germline BRCA Gene Mutational Status
por: Logue, Chloe A., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_7guodl7d8tn8h2ldg8q6501ibm